Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7241
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia ; day:8 ; month:2 ; year:2019 ; pages:1-8
Cardiovascular drugs and therapy ; (8.2.2019), 1-8
- Creator
-
Ginsberg, Henry N.
Tuomilehto, Jaakko
Hovingh, G. Kees
Cariou, Bertrand
Santos, Raul D.
Brown, Alan S.
Sanganalmath, Santosh K.
Koren, Andrew
Thompson, Desmond
Raal, Frederick J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10557-019-06852-6
- URN
-
urn:nbn:de:101:1-2019031014532426118010
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Ginsberg, Henry N.
- Tuomilehto, Jaakko
- Hovingh, G. Kees
- Cariou, Bertrand
- Santos, Raul D.
- Brown, Alan S.
- Sanganalmath, Santosh K.
- Koren, Andrew
- Thompson, Desmond
- Raal, Frederick J.
- SpringerLink (Online service)
Other Objects (12)
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
P5.22: Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia
Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia
Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)
A mini-review of efficacy, safety, and influence of novel evinacumab on familial hypercholesterolemia
Long-term cancer risk in heterozygous familial hypercholesterolemia relatives: a 25-year cohort study
Familial Hypercholesterolemia: new therapeutic approaches
Sex Differences in Familial Hypercholesterolemia
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
Familial Hypercholesterolemia: Present and Future Management
The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia
Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
P5.22: Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia
Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia
Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)
A mini-review of efficacy, safety, and influence of novel evinacumab on familial hypercholesterolemia
Long-term cancer risk in heterozygous familial hypercholesterolemia relatives: a 25-year cohort study
Familial Hypercholesterolemia: new therapeutic approaches
Sex Differences in Familial Hypercholesterolemia
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
Familial Hypercholesterolemia: Present and Future Management
The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia
Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
P5.22: Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia
Lipoprotein(a) is associated with DNA damage in patients with heterozygous familial hypercholesterolemia
Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)
A mini-review of efficacy, safety, and influence of novel evinacumab on familial hypercholesterolemia
Long-term cancer risk in heterozygous familial hypercholesterolemia relatives: a 25-year cohort study
Familial Hypercholesterolemia: new therapeutic approaches
Sex Differences in Familial Hypercholesterolemia
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
Familial Hypercholesterolemia: Present and Future Management
The Clinical Importance of Differentiating Monogenic Familial Hypercholesterolemia from Polygenic Hypercholesterolemia